--- title: "Non-Inferiority Trial, Definition | MedTech Terms" description: "A trial designed to demonstrate that a new intervention is not worse than an active comparator by more than a pre-specified, clinically acceptable margin." lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/non-inferiority-trial#term", "name": "Non-Inferiority Trial", "alternateName": "NI trial", "description": "A non-inferiority trial is designed to demonstrate that a new intervention is not unacceptably worse than an active comparator. The pre-specified non-inferiority margin (delta) defines the largest difference that would still be considered clinically acceptable; a one-sided 95% confidence interval that excludes a difference worse than the margin establishes non-inferiority. Common in MedTech when a placebo or sham control would be unethical (e.g., comparing a new drug-eluting stent against an established one).", "url": "https://medtechterms.com/terms/non-inferiority-trial", "termCode": "non-inferiority-trial", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/non-inferiority-trial#article", "headline": "Non-Inferiority Trial", "description": "A trial designed to demonstrate that a new intervention is not worse than an active comparator by more than a pre-specified, clinically acceptable margin.", "url": "https://medtechterms.com/terms/non-inferiority-trial", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/non-inferiority-trial" }, "about": { "@id": "https://medtechterms.com/terms/non-inferiority-trial#term" }, "articleSection": "Clinical & Trials", "inLanguage": "en", "keywords": "Non-Inferiority Trial, NI trial, Clinical & Trials, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-09", "dateModified": "2026-05-09", "citation": [ { "@type": "CreativeWork", "name": "FDA Guidance, Non-Inferiority Clinical Trials (2016)", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials", "publisher": { "@type": "Organization", "name": "FDA" } }, { "@type": "CreativeWork", "name": "ICH E10 Choice of Control Group", "url": "https://www.ich.org/page/efficacy-guidelines", "publisher": { "@type": "Organization", "name": "ICH" } }, { "@type": "CreativeWork", "name": "ICH Guidelines", "url": "https://www.ich.org/page/ich-guidelines", "publisher": { "@type": "Organization", "name": "ICH" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pivotal-trial#term", "name": "Pivotal Trial", "url": "https://medtechterms.com/terms/pivotal-trial" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/adaptive-trial#term", "name": "Adaptive Trial Design", "url": "https://medtechterms.com/terms/adaptive-trial" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/ich-gcp#term", "name": "ICH E6 Good Clinical Practice", "alternateName": "GCP", "url": "https://medtechterms.com/terms/ich-gcp" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/composite-endpoint#term", "name": "Composite Endpoint", "url": "https://medtechterms.com/terms/composite-endpoint" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Clinical & Trials", "item": "https://medtechterms.com/terms?cat=Clinical%20%26%20Trials" }, { "@type": "ListItem", "position": 4, "name": "Non-Inferiority Trial", "item": "https://medtechterms.com/terms/non-inferiority-trial" } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Clinical & Trials](/terms?cat=Clinical%20%26%20Trials) 6. / 7. Non-Inferiority Trial [All terms](/terms) Clinical & Trials [Clinical Evidence](/ecosystems/clinical-evidence) # Non-Inferiority Trial A trial designed to demonstrate that a new intervention is not worse than an active comparator by more than a pre-specified, clinically acceptable margin. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 9, 2026 ## Definition A non-inferiority trial is designed to demonstrate that a new intervention is not unacceptably worse than an active comparator. The pre-specified non-inferiority margin (delta) defines the largest difference that would still be considered clinically acceptable; a one-sided 95% confidence interval that excludes a difference worse than the margin establishes non-inferiority. Common in MedTech when a placebo or [sham control](/terms/sham-control) would be unethical (e.g., comparing a new drug-eluting stent against an established one). What the regulation says FDA Guidance: 'Non-Inferiority Clinical Trials to Establish Effectiveness' (November 2016). EMA: CHMP Points to Consider on Non-Inferiority. ICH E10 'Choice of Control Group' provides the foundational framework. ## What this means in practice Margin selection is the most contested element. FDA expects the margin to be both clinically defensible and to preserve a meaningful fraction of the comparator's effect over placebo (the 'M1/M2' framework). Common pitfalls - • Choosing a margin that's clinically defensible but doesn't preserve enough of the active comparator's effect, FDA will reject the design. - • Running a non-inferiority trial with poor protocol adherence, drift biases toward the null and toward false NI conclusions. ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Clinical & Trials Adaptive Trial Design Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data. ](/terms/adaptive-trial)[ Clinical & Trials Composite Endpoint Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke). ](/terms/composite-endpoint)[ Clinical & Trials ICH E6 Good Clinical Practice(GCP) International standard for the design, conduct, and reporting of clinical trials. ](/terms/ich-gcp)[ Clinical & Trials Pivotal Trial Definitive clinical study designed to establish safety and effectiveness for marketing authorization. ](/terms/pivotal-trial) ### More in Clinical & Trials · Same category [ Clinical & Trials Adverse Event(AE) Any untoward medical occurrence in a subject, whether or not related to the device. ](/terms/adverse-event)[ Clinical & Trials ALCOA+ Data integrity principles: Attributable, Legible, Contemporaneous, Original, Accurate (plus Complete, Consistent, Enduring, Available). ](/terms/alcoa-plus)[ Clinical & Trials Analytical Sensitivity An IVD's ability to detect small quantities of an analyte. ](/terms/analytical-sensitivity)[ Clinical & Trials Bayesian Trial Design Trial design that uses Bayesian statistics, often incorporating prior data from related studies or registries. ](/terms/bayesian-trial) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Clinical Evidence](/ecosystems/clinical-evidence) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 FDA· 1 ICH· 2 1. [1 FDA Guidance, Non-Inferiority Clinical Trials (2016) Verified FDA · fda.gov ](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials) 2. [2 ICH E10 Choice of Control Group Verified ICH · ich.org ](https://www.ich.org/page/efficacy-guidelines) 3. [3 ICH Guidelines Verified ICH · ich.org ](https://www.ich.org/page/ich-guidelines) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Clinical evidence intersecting with device security? We support clinical-stage MedTech teams whose investigational devices touch patient data or hospital networks. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Clinical & Trials Sources 3 Updated 5/9/2026 [Compare with another term](/compare?a=non-inferiority-trial) Learn in 60 seconds Card Lesson Quiz A trial designed to demonstrate that a new intervention is not worse than an active comparator by more than a pre-specified, clinically acceptable margin. - · Margin selection is the most contested element. - · FDA expects the margin to be both clinically defensible and to preserve a meaningful fraction of the comparator's effect over placebo (the 'M1/M2' framework). - · Common in MedTech when a placebo or sham control would be unethical (e.g., comparing a new drug-eluting stent against an established one). Remember this Watch out: Choosing a margin that's clinically defensible but doesn't preserve enough of the active comparator's effect, FDA will reject the design. Related terms - [Pivotal Trial ](/terms/pivotal-trial) - [Adaptive Trial Design ](/terms/adaptive-trial) - [ICH E6 Good Clinical Practice(GCP) ](/terms/ich-gcp) - [Composite Endpoint ](/terms/composite-endpoint) You may also need Auto-suggested from Clinical & Trials and shared keywords. - [Sham Control ](/terms/sham-control) - [Master Protocol (Basket / Umbrella / Platform) ](/terms/master-protocol) - [Minimal Clinically Important Difference(MCID) ](/terms/mcid) - [Primary and Secondary Endpoints ](/terms/primary-secondary-endpoint) - [Sample Size and Statistical Power ](/terms/sample-size-power) - [Surrogate Endpoint ](/terms/surrogate-endpoint) [All Clinical & Trials terms](/terms?cat=Clinical%20%26%20Trials) From the Blue Goat network Related resources and services on this topic. - [ MedTech Launchpad MedTech funding rounds, accelerators, and launch resources. ](https://medtechlaunchguide.com) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)